FIELD: medicine.
SUBSTANCE: the present innovation deals with applying heparin of average molecular weight ranged 10-11.5 kDa, mostly 10.5 kDa. The suggested heparin should be obtained due to controlled depolymerization of nonfractionated heparin and subsequent isolation with the methods of molecular filtration. It is indicated to manufacture medicinal preparation for preventing and treating thromboembolic processes and, in particular, for inhibiting blood clotting in case of extracorporal circulation. The present heparin against the known ones is characterized by the absence of bleeding at the highest activity against factor IIa that significantly increases its therapeutic index.
EFFECT: higher efficiency.
1 cl, 8 dwg, 3 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREPARING HEPARIN WITH LOW MOLECULAR WEIGHT AND ANTICOAGULANT ACTIVITY | 2009 |
|
RU2396282C1 |
METHOD FOR MAKING LOW-MOLECULAR HEPARIN | 2007 |
|
RU2377993C2 |
ANTITHROMBOTIC AGENT OF SIBERIAN FIR CELLULOSE | 2014 |
|
RU2571555C1 |
METHOD OF OBTAINING LOW-MOLECULAR HEPARIN | 2012 |
|
RU2512768C1 |
ANTICOAGULANT | 2009 |
|
RU2399377C1 |
AGENT WITH ANTITHROMBOTIC ACTIVITY | 2016 |
|
RU2627435C1 |
METHOD FOR PREVENTION OF DESULPHATION AND HIGH BIOAVAILABILITY OF BIOLOGICALLY ACTIVE SULPHATED ORAL POLYSACCHARIDES | 2009 |
|
RU2421230C2 |
AGENT WITH ANTICOAGULATING EFFECT AND ITS APPLICATION METHOD | 2021 |
|
RU2799028C2 |
ANTICOAGULATING BIOLOGICALLY ACTIVE COMPLEX MADE OF SIBERIAN CEDAR BARK | 2007 |
|
RU2366441C2 |
METHOD FOR OBTAINING NADROPARIN CALCIUM | 2020 |
|
RU2753678C1 |
Authors
Dates
2008-04-20—Published
2000-12-22—Filed